Related Experiment Video

Updated: Nov 7, 2025

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

13.8K

RO4929097 regulates RANKL-induced osteoclast formation and LPS-mediated bone resorption

Tao Huang1, Congyun Zhao2, Yi Zhao1

  • 1Department of Orthopaedics, Baoshan Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Aging
|May 2, 2021
PubMed

Insights

RO4929097, a potent gamma-secretase inhibitor, effectively suppresses osteoclast formation and bone resorption. This compound targets the Notch pathway, offering potential for treating osteolytic diseases.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Osteoclastogenesis, driven by RANKL, is crucial for bone remodeling.
  • Dysregulated osteoclast activity contributes to osteolytic diseases.
  • Targeting osteoclast formation is a therapeutic strategy for bone disorders.

Purpose of the Study:

  • To investigate the inhibitory effect of RO4929097, a gamma-secretase inhibitor, on RANKL-induced osteoclastogenesis.
  • To elucidate the molecular mechanisms underlying RO4929097's suppressive function.
  • To evaluate the therapeutic potential of RO4929097 in vivo.

Main Methods:

  • In vitro assessment of RO4929097 cytotoxicity and its effects on osteoclast formation and resorption.
  • Quantitative PCR (qPCR) to analyze gene expression, including NFATc1.
  • In vivo studies using LPS-induced bone resorption models in mice.

Main Results:

  • RO4929097 demonstrated a cytotoxicity IC50 of 2.93 μM.
  • Dose-dependent reduction in osteoclast number and resorption area by RO4929097.
  • RO4929097 attenuated RANKL-induced NFATc1 expression and inhibited LPS-induced bone resorption in vivo.

Conclusions:

  • RO4929097 potently inhibits osteoclastogenesis and bone resorption via down-regulation of the Notch/MAPK/JNK/Akt pathway and NFATc1.
  • RO4929097 shows therapeutic potential in preclinical models of osteolytic diseases.
  • The Notch pathway is a potential therapeutic target for osteolytic diseases.
Keywords:
NotchRANKLRO4929097bone resorptionosteoclasts

More Related Videos

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro07:03

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro

Published on: June 16, 2022

6.8K
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.9K

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.5K
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
39.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.9K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.4K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.7K
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
14.5K